BioLineRx Reports Preclinical GLIX1 Synergy With PARP Inhibitors

BioLineRx reported at ESMO 2026 that GLIX1 synergized with multiple PARP inhibitors in HR-proficient ovarian cancer cell lines and a PDX model. The low-dose GLIX1 and olaparib combination significantly inhibited tumor growth versus vehicle.